Morphic Holding, Inc. (MORF)

NASDAQ: MORF · IEX Real-Time Price · USD
37.22
-0.41 (-1.09%)
Mar 24, 2023, 4:00 PM EDT - Market closed
-1.09%
Market Cap 1.55B
Revenue (ttm) 70.81M
Net Income (ttm) -59.04M
Shares Out 41.52M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 570,221
Open 37.33
Previous Close 37.63
Day's Range 35.89 - 37.64
52-Week Range 19.23 - 49.24
Beta 1.18
Analysts Buy
Price Target 60.18 (+61.69%)
Earnings Date May 2, 2023

About MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibroti... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2019
Employees 103
Stock Exchange NASDAQ
Ticker Symbol MORF
Full Company Profile

Financial Performance

In 2022, MORF's revenue was $70.81 million, an increase of 257.72% compared to the previous year's $19.79 million. Losses were -$59.04 million, -38.20% less than in 2021.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for MORF stock is "Buy." The 12-month stock price forecast is $60.18, which is an increase of 61.69% from the latest price.

Price Target
$60.18
(61.69% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Morphic to Present at TD Cowen 43rd Annual Health Care Conference

WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chron...

3 weeks ago - GlobeNewsWire

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23-

1 month ago - GlobeNewsWire

Morphic to Present at SVB Leerink Global Healthcare Conference

WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chroni...

1 month ago - GlobeNewsWire

Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...

2 months ago - Zacks Investment Research

Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chroni...

2 months ago - GlobeNewsWire

Morphic Announces Participation in 2022 Jefferies London Healthcare Conference

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch...

4 months ago - GlobeNewsWire

Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 2.50% and 46.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc...

5 months ago - Zacks Investment Research

Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022

Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule

5 months ago - GlobeNewsWire

Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Saturating receptor occupancy at 100 and 200 mg BID doses

5 months ago - GlobeNewsWire

Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections

Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow patients currently screened to enter study if eligible Phase 2a trial of MORF-057 in patients with ulcera...

5 months ago - GlobeNewsWire

Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations

5 months ago - GlobeNewsWire

Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...

6 months ago - Zacks Investment Research

Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree

Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders

6 months ago - GlobeNewsWire

Morphic Celebrates Foundational Integrin Research Published in Cell

Paper describes key insight into integrin conformation, overcoming critical drug development challenge

6 months ago - GlobeNewsWire

Wall Street Analysts Predict a 108% Upside in Morphic Holding, Inc. (MORF): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questiona...

7 months ago - Zacks Investment Research

Can Morphic Holding, Inc. (MORF) Climb 97% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 96.7% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionab...

8 months ago - Zacks Investment Research

Morphic Holding, Inc. (MORF) Surpasses Q2 Earnings and Revenue Estimates

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 183.95% and 1,317.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc...

8 months ago - Zacks Investment Research

Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022

Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis

8 months ago - GlobeNewsWire

Morphic Holding, Inc. (MORF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Morphic Holding, Inc. (MORF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Morphic to Present at 2022 Jefferies Global Healthcare Conference

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch...

10 months ago - GlobeNewsWire

Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple Therapeutic Areas Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple ...

11 months ago - GlobeNewsWire

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue Estimates

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -19.72% and 52.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022

Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis

11 months ago - GlobeNewsWire

Strength Seen in Morphic Holding, Inc. (MORF): Can Its 7% Jump Turn into More Strength?

Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...

11 months ago - Zacks Investment Research

Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious c...

1 year ago - GlobeNewsWire